Electrophysiologic Complications in Cancer Patients
References
- Siegel RL Miller KD Jemal A Cancer statistics, 2018 CA Cancer J Clin 2018 Jan 68 1 7 30
- Buza V Rajagopalan B Curtis AB Cancer Treatment-Induced Arrhythmias: Focus on Chemotherapy and Targeted Therapies Circ Arrhythm Electrophysiol 2017 Aug 10 8
- Mahmood SS Fradley MG Cohen JV Myocarditis in Patients Treated With Immune Checkpoint Inhibitors J Am Coll Cardiol 2018 Apr 24 71 16 1755 64
- January CT Wann LS Calkins H 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 2019 Jul 9 74 1 104 32
- Tamargo J Caballero R Delpón E Cancer chemotherapy and cardiac arrhythmias: a review Drug Saf 2015 Feb 38 2 129 52
- Feliz V Saiyad S Ramarao SM Khan H Leonelli F Guglin M Melphalan-induced supraventricular tachycardia: incidence and risk factors Clin Cardiol 2011 Jun 34 6 356 9
- Kilickap S Barista I Akgul E Aytemir K Aksoy S Tekuzman G Early and late arrhythmogenic effects of doxorubicin South Med J 2007 Mar 100 3 262 5
- Mazur M Wang F Hodge DO Burden of Cardiac Arrhythmias in Patients With Anthracycline-Related Cardiomyopathy JACC Clin Electrophysiol 2017 Feb 3 2 139 50
- Fradley MG Viganego F Kip K Rates and risk of arrhythmias in cancer survivors with chemotherapy-induced cardiomyopathy compared with patients with other cardiomyopathies Open Heart 2017 Dec 17 4 2 e000701
- Zellos L Richards WG Capalbo L A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma J Thorac Cardiovasc Surg 2009 Feb 137 2 453 8
- Petrini I Lencioni M Ricasoli M Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma Cancer Chemother Pharmacol 2012 Mar 69 3 773 80
- Byrd JC Brown JR O'Brien S RESONATE Investigators Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia N Engl J Med 2014 Jul 17 371 3 213 23
- Fradley MG Gliksman M Emole J Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy Am J Cardiol 2019 Aug 15 124 4 539 544
- Leong DP Caron F Hillis C The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis Blood 2016 Jul 7 128 1 138 40
- Wiczer TE Levine LB Brumbaugh J Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib Blood Adv 2017 Sep 8 1 20 1739 48
- Mato AR Clasen S Pickens P Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia Cancer Biol Ther 2018 Jan 2 19 1 1 2
- McMullen JR Boey EJ Ooi JY Seymour JF Keating MJ Tam CS Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling Blood 2014 Dec 11 124 25 3829 30
- Lee DH Fradley MG Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention Curr Treat Options Cardiovasc Med 2018 Mar 6 20 3 19
- Heinzerling L Ott PA Hodi FS Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy J Immunother Cancer 2016 Aug 16 4 50
- Alvi RM Mahmood S Hassan MZO The cardiovascular effects of chimeric antigen receptor T-cells J Am Coll Cardiol 2019 Mar 73 9 Suppl 1 722
- January CT Wann LS Alpert JS American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 2014 Dec 2 64 21 e1 76
- D'Souza M Carlson N Fosbøl E CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer Eur J Prev Cardiol 2018 Apr 25 6 651 8
- Hu WS Lin CL Impact of atrial fibrillation on the development of ischemic stroke among cancer patients classified by CHA2DS2-VASc score-a nationwide cohort study Oncotarget 2018 Jan 10 9 7 7623 30
- Lip GY Frison L Halperin JL Lane DA Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score J Am Coll Cardiol 2011 Jan 11 57 2 173 80
- Fradley M Ellenberg K Swanson J Patterns of anticoagulation use in cancer patients with atrial fibrillation and/or atrial flutter J Am Coll Cardiol 2019 Mar 73 9 Suppl 1 504
- Shah S Norby FL Datta YH Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation Blood Adv 2018 Feb 13 2 3 200 9
- Wang ML Rule S Martin P Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma N Engl J Med 2013 Aug 8 369 6 507 16
- Ganatra S Sharma A Shah S Ibrutinib-Associated Atrial Fibrillation JACC Clin Electrophysiol 2018 Dec 4 12 1491 1500
- Fradley MG Moslehi J QT Prolongation and Oncology Drug Development Card Electrophysiol Clin 2015 Jun 7 2 341 55
- Naing A Veasey-Rodrigues H Hong DS Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs Ann Oncol 2012 Nov 23 11 2960 3
- Lenihan DJ Kowey PR Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors Oncologist 2013 18 8 900 8
- Roboz GJ Ritchie EK Carlin RF Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic tri-oxide J Clin Oncol 2014 Nov 20 32 33 3723 8
- US Food and Drug Administration [Internet] Silver Spring, MD US Food and Drug Administration 2019 Warning: Differentiation syndrome and cardiac conduction abnormalities; 2019 [cited 2019 Jul 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021248s015lbl.pdf
- National Comprehensive Cancer Network [Internet] Plymouth Meeting, PA National Comprehensive Cancer Network 2019 Cancer-associated venous thromboembolic disease; 2018 Feb [cited 2019 Jul 22]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf
- Infante JR Cassier PA Gerecitano JF A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas Clin Cancer Res 2016 Dec 1 22 23 5696 705
- Armanious MA Mishra S Fradley MG Electrophysiologic Toxicity of Chemo-radiation Curr Oncol Rep 2018 Apr 11 20 6 45
- Abdel-Rahman O Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis Immunotherapy 2019 Apr 11 6 543 54
- Porta-Sánchez A Gilbert C Spears D Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review J Am Heart Assoc 2017 Dec 7 6 12
- Fradley MG Pinilla-Ibarz J Arrhythmic complications of tyrosine kinase inhibitors Future Cardiol 2015 Jul 11 4 395 9
- Kim TD le Coutre P Schwarz M Clinical cardiac safety profile of nilotinib Haematologica 2012 Jun 97 6 883 9
- Zang J Wu S Tang L Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis PLoS One 2012 7 2 e30353
- Porta-Sánchez A Gilbert C Spears D Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review J Am Heart Assoc 2017 Dec 7 6 12
- Guha A Derbala MH Zhao Q Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies J Am Coll Cardiol 2018 Aug 7 72 6 697 8
- Ou SH Tang Y Polli A Wilner KD Schnell P Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007) Cancer Med 2016 Apr 5 4 617 22
- Zhang Z Huang TQ Nepliouev I Crizotinib Inhibits Hyperpolarization-activated Cyclic Nucleotide-Gated Channel 4 Activity Cardiooncology 2017 3
- McGuire WP Rowinsky EK Rosenshein NB Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms Ann Intern Med 1989 Aug 15 111 4 273 9
- Arbuck SG Strauss H Rowinsky E A reassessment of cardiac toxicity associated with Taxol J Natl Cancer Inst Monogr 1993 15 117 30
- Johnson DB Balko JM Compton ML Fulminant Myocarditis with Combination Immune Checkpoint Blockade N Engl J Med 2016 Nov 3 375 18 1749 55
- Zaremba T Jakobsen AR Søgaard M Risk of device malfunction in cancer patients with implantable cardiac device undergoing radiotherapy: a population-based cohort study Pacing Clin Electrophysiol 2015 Mar 38 3 343 56
- Viganego F Singh R Fradley MG Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation Curr Cardiol Rep 2016 Jun 18 6 52
- Grant JD Jensen GL Tang C Radiotherapy-Induced Malfunction in Contemporary Cardiovascular Implantable Electronic Devices: Clinical Incidence and Predictors JAMA Oncol 2015 Aug 1 5 624 32
- Brambatti M Mathew R Strang B Management of patients with implantable cardioverter-defibrillators and pacemakers who require radiation therapy Heart Rhythm 2015 Oct 12 10 2148 54
DOI: https://doi.org/10.14797/mdcj-15-4-282 | Journal eISSN: 1947-6108
Language: English
Page range: 282 - 288
Published on: Oct 1, 2019
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2019 Dae Hyun Lee, Sanjay Chandrashekhar, Michael G. Fradley, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.